Abstract
The recent BIOFLOW V trial (ClinicalTrials.gov: [NCT02389946][1]) showed that the Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent (BP SES) (Biotronik, Buelach, Switzerland) had lower rates of both clinically driven target lesion revascularization (TLR) and target vessel-related
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
